News
Client MNRs and Landing Pages
Since 2004, brands have counted on Cision’s MultiVu to create and distribute their important news and marketing content to the world.
Let's talkSearch our recent client collaborations below:
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 3, 2025International Paper and DS Smith, two of the leading producers of sustainable packaging, containerboard and pulp products, combined forces on January 31, 2025International Paper and DS Smith, two of the leading producers of sustainable packaging, containerboard and pulp products, combined forces on January 31, 2025
- Feb 3, 2025International Paper (NYSE : IP ; LSE : IPC) et DS Smith, deux des principaux producteurs d'emballage, de carton et de pâte durables, ont uni leurs forces le 31 janvier 2025
Nous sommes plus forts ensemble. En savoir plus. International Paper et DS Smith fusionnent pour créer le nouveau leader mondial des solutions d'emballage durables Anglais Allemande Espagnole...
Feb 3, 2025International Paper (NYSE:IP; LSE: IPC) und DS Smith, zwei führende Hersteller von nachhaltigen Verpackungs-, Kartonage- und Zellstoffprodukten, haben am 31. Januar 2025We are stronger together. Learn more here. International Paper und DS Smith schließen sich zusammen, um den neuen Weltmarktführer für nachhaltige Verpackungslösungen zu schaffen French Spanish...
- Feb 3, 2025International Paper (NYSE:IP; LSE: IPC) y DS Smith, dos de los principales productores de embalajes sostenibles, cartón para contenedores y productos de pulpa, unieron sus fuerzas el 31 de enero de 2025
We are stronger together. Learn more here. International Paper y DS Smith se unen para crear el nuevo líder mundial en soluciones de embalaje sostenible French German English MEMPHIS, Tenn., 3 de...
Jan 31, 2025SYMBRAVO represents a novel multi-mechanistic approach for the acute treatment of migraine that addresses the four key pathways underlying a migraine attackAxsome Therapeutics’ SYMBRAVO™ (meloxicam and rizatriptan) Approved by the U.S. Food and Drug Administration for the Acute Treatment of Migraine with or without Aura in Adults Lorem ipsum...
Connect with us: